Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL1FG3
|
|||
| Drug Name |
SAR440234
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1/2 | [1] | |
| leukaemia [ICD-11: 2A60-2B33; ICD-10: C91-C95; ICD-9: 204-208] | Phase 1/2 | [1] | ||
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 3 receptor alpha (IL3RA) | Target Info | . | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Apoptosis | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL3 Signaling Pathway | ||||
| Pathway Interaction Database | IL3-mediated signaling events | |||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| RAF/MAP kinase cascade | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-3 Signaling Pathway | |||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03594955) First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.